Abnormal Involuntary Movement Rating Scale News Today : Breaking News, Live Updates & Top Stories | Vimarsana

/PRNewswire/ Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented findings from a meta-analysis of three long-term studies evaluating INGREZZA®.

South koreaLas vegasNeurocrine biosciencesEiryw robertsExchange commissionNeurocrine biosciences incAbnormal involuntary movement rating scaleMitsubishi tanabe pharma corporationPsych congress elevateAbnormal involuntary movement scaleCongress elevateChief medical officerPsychiatric stabilityAdults with tardive dyskinesiaMood disorderPost hoc analyses